Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cassiopea SpA    SKIN   IT0005108359

CASSIOPEA SPA (SKIN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 11:31:12 am
41.2 CHF   +0.49%
2018CASSIOPEA SPA : half-yearly earnings release
2017CASSIOPEA SPA : half-yearly earnings release
2017CASSIOPEA SPA : annual earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
39.5(c) 39.8(c) 40.2(c) 41(c) 41.2(c) Last
3 987 4 145 7 689 1 701 3 146 Volume
0.00% +0.76% +1.01% +1.99% +0.49% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -12,4 M
Net income 2018 -12,0 M
Finance 2018 17,3 M
Yield 2018 -
Sales 2019 -
EBIT 2019 -32,3 M
Net income 2019 -35,7 M
Finance 2019 52,4 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 0
Capitalization 364 M
More Financials
Company
Cassiopea SpA is an Italy-based company engaged in the biotechnology and medical research industry. The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. The Company's current focus is... 
Sector
Pharmaceuticals
Calendar
02/21Earnings Release
More about the company
Surperformance© ratings of Cassiopea SpA
Trading Rating : Investor Rating : -
More Ratings
Latest news on CASSIOPEA SPA
2018Cassiopea announces attainment of all primary and secondary endpoints and hig..
TE
2018Cassiopea enters into loan agreement with Cosmo Pharmaceuticals NV
TE
2018CASSIOPEA : Command and control system
AQ
2018Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for C..
TE
2018Cassiopea Announces Results for First Half of 2018
TE
2018Cassiopea Announces Very Positive Interim Analysis Phase 2 Results for Breezu..
TE
2018CASSIOPEA SPA : half-yearly earnings release
2018EUROPE : European shares extend recovery rally as oil stocks lead
RE
2018Cassiopea Announces Very Positive Top-Line Phase 3 Results for Winlevi® (Clas..
TE
2018Results of the ordinary and extraordinary shareholders meeting 2018
TE
More news
Analyst Recommendations on CASSIOPEA SPA
More recommendations
Sector news : Specialty & Advanced Pharmaceuticals
01/18ELI LILLY AND : Lilly Reports Favorable Cyramza Results in Phase 3 Liver Cancer ..
DJ
01/18ABBVIE : Says Imbruvica Didn't Meet Endpoints in Pancreatic Cancer Study
DJ
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/18FDA Approves Herceptin Biosimilar Ontruzant Breast Cancer Drug
DJ
01/18ELI LILLY AND : Sarcoma Drug Combo Proves Ineffective in Trials--Update
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Chart CASSIOPEA SPA
Duration : Period :
Cassiopea SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSIOPEA SPA
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 69,1 €
Spread / Average Target 90%
EPS Revisions
Managers
NameTitle
Diana Harbort Chief Executive Officer & Executive Director
Jan Egbert de Vries Non-Executive Chairman
Marco Pasero Chief Operating Officer
Hans Christoph Tanner CFO, Head-Investor & Media Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CASSIOPEA SPA12.57%414
ABBVIE-2.92%134 627
MERCK KGAA0.58%13 287
KYOWA HAKKO KIRIN CO LTD4.39%11 108
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD4.54%8 065
JAZZ PHARMACEUTICALS PLC4.12%7 786